FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?

van Rhijn BW, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJ, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, van der Heijden MS, Jewett MA, Marquez M, Stöhr R, Zlotta AR, Eckstein M, Soorojebally Y, Roshani H, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, Wullich B, van der Kwast TH, Malats N, Hartmann A, Allory Y, Zuiverloon TCM (2020)

Publication Type: Journal article

Publication year: 2020

Journal

DOI: 10.1016/j.eururo.2020.07.002

Abstract

Oncogenic fibroblast growth factor receptor 3 (FGFR3) mutations were associated with favorable bladder cancer in a series of 1000 radical cystectomy cases. Moreover, patients with FGFR3 mutant tumors would be more likely to benefit from anti-FGFR3 therapy than patients with overexpression only.

Authors with CRIS profile

Involved external institutions

Erasmus University Medical Center (MC) Netherlands (NL) Spanish National Cancer Research Centre / Centro Nacional de Investigaciones Oncológicas (CNIO) Spain (ES) University of Toronto Canada (CA) Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL) Netherlands (NL) Institut Curie France (FR) Universitätsklinikum Regensburg Germany (DE) Universität Regensburg Germany (DE) HagaZiekenhuis Netherlands (NL)

How to cite

APA:

van Rhijn, B.W., Mertens, L.S., Mayr, R., Bostrom, P.J., Real, F.X., Zwarthoff, E.C.,... Zuiverloon, T.C.M. (2020). FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? European Urology. https://doi.org/10.1016/j.eururo.2020.07.002

MLA:

van Rhijn, Bas W.G., et al. "FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?" European Urology (2020).

BibTeX: Download